More on ALXN
Data
Financials
Upcoming Events
News
Click line-items for a historical chart and %
| Condensed Consolidated Statements Of Operations | |
| Net product sales | 752.55M |
| Cost of sales | 60.63M |
| Operating expenses: | |
| Research and development | 179.31M |
| Selling, general and administrative | 231.8M |
| Acquisition-related costs | |
| Amortization of purchased intangible assets | |
| Total operating expenses | 497.78M |
| Operating income | 194.71M |
| Other income and expense: | |
| Investment income | 1.87M |
| Interest expense | -23.79M |
| Foreign currency loss | -2.82M |
| Income before income taxes | 169.97M |
| Income tax provision | 55.02M |
| Net income | 114.94M |
| Earnings per common share | |
| Basic | 0.51 |
| Diluted | 0.51 |
| Shares used in computing earnings per common share | |
| Basic | 224.09M |
| Diluted | 225.76M |
Entities mentioned with ALXN
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- FDA | View Related Stories »
- JPMorgan | View Related Stories »
- Morgan Stanley | View Related Stories »
- Citi | View Related Stories »
- AdCom | View Related Stories »
- Pre Market Movers | View Related Stories »
- Show More...
